BACE1 and Alzheimer disease: In vivo studies in the APP/PS1 transgenic mouse model of AD showed that calpain activation resulted in dramatically increased Aβ levels and plaque deposition and that this was most likely mediated through elevations in BACE1 level and activity (Liang et al., 2010).